ISRCTN ISRCTN92716512
DOI https://doi.org/10.1186/ISRCTN92716512
Secondary identifying numbers CVVHD- Ci-Ca-01-EU
Submission date
26/08/2008
Registration date
04/12/2008
Last edited
30/09/2015
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Stanislao Morgera
Scientific

Universitätskrankenhaus Charité
Medizinische Klinik - Nephrologie
Berlin
10117
Germany

Study information

Study designProspective observational open multi-centre study
Primary study designObservational
Secondary study design
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleCitrate anticoagulation during continuous veno-venous haemodialysis (CVVHD) - an observational study
Study acronymLCAT study
Study objectives1. Assessment of the safety and efficacy of regional citrate anticoagulation during continuous veno-venous haemodialysis (CVVHD) using multiFiltrate with the Ci-Ca System®
2. Investigation of the impact of liver failure on safety, efficacy and dosing schemes of this procedure
Ethics approval(s)Ethics Committee of Charité - University Medicine Berlin (Charité - Universitätsmedizin Berlin), 27/07/2007, ref: EA1/101/07
Health condition(s) or problem(s) studiedIntensive care patients with renal failure
InterventionEvery patient will be observed for 72 hours after the start of the Ci-Ca CVVHD treatment. The participation in the study and the data collection will be terminated before 72 hours if the patient does not require a Ci-Ca CVVHD treatment any more.
Intervention typeOther
Primary outcome measureMain end-points for the safety evaluation is the occurrence of citrate metabolic complications (hypocalcemia, hypercalcemia, alkalosis, acidosis).

For the efficacy evaluation main end-points are: the percentage of functioning filters after 72 treatment hours and post-filter ionized calcium.
Secondary outcome measuresNo secondary outcome measures
Overall study start date07/12/2007
Completion date31/12/2009

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants120
Key inclusion criteria1. Adult patients (at least 18 years old, both males and females) treated on intensive care unit (ICU) due to renal failure requiring CVVHD and citrate anticoagulation (treatment with the multiFiltrate Ci-Ca System®)
2. Patient (or his legal representative or the next of kin - according to the local requirements) written informed consent
Key exclusion criteria1. Use of regional citrate anticoagulation in the period of 72 hours preceding the enrolment in the study
2. Concomitant participation in another clinical trial
3. Previous participation in the same study
Date of first enrolment07/12/2007
Date of final enrolment31/12/2009

Locations

Countries of recruitment

  • Austria
  • Germany
  • Norway
  • Switzerland
  • United Kingdom

Study participating centre

Universitätskrankenhaus Charité
Berlin
10117
Germany

Sponsor information

Fresenius Medical Care (Germany)
Industry

Else-Kröner-Str. 1
Bad Homburg
61352
Germany

Website http://www.fmc-ag.com
ROR logo "ROR" https://ror.org/04sk0bj73

Funders

Funder type

Industry

Fresenius Medical Care (Germany)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/02/2011 Yes No
Results article results 29/09/2015 Yes No